Fig. 3: sMVA in vivo immunogenicity.
From: Development of a multi-antigenic SARS-CoV-2 vaccine candidate using a synthetic poxvirus platform
sMVA derived either with FPV HP1.441 (sMVA hp) or with FPV TROVAC from two independent virus reconstitutions (sMVA tv1 and sMVA tv2) was compared by in vivo analysis with wtMVA. C57BL/6 mice (n = 4) were immunized twice at a 3-week interval with low (1 × 107 PFU) or high (5 × 107 PFU) dose of sMVA or wtMVA. Mock-immunized mice were used as controls. a Binding antibodies. MVA-specific binding antibodies (IgG titer) stimulated by sMVA or wtMVA were measured after the first and second immunization by ELISA. b NAb responses. MVA-specific NAb titers induced by sMVA or wtMVA were measured after the booster immunization against recombinant wtMVA expressing a GFP marker. c, d T-cell responses. MVA-specific IFNγ, TNFα, IL-4, and IL-10-secreting CD8+ (c) and CD4+ (d) T-cell responses induced by sMVA or wtMVA after two immunizations were measured by flow cytometry following ex vivo antigen stimulation using B8R immunodominant peptides. Differences between groups were evaluated using one-way ANOVA with Tukey’s multiple comparison test; ns = not significant (p > 0.05). Data in a and b are presented as mean values + SD. Lines in c and d represent median values. Source data are provided as a Source Data file.
